Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Anteris Technologies Global Corp.

Contributing Author

Recent Articles by Anteris Technologies Global Corp.

Aug-11
Anteris Technologies Announces Results for the Second Quarter of 2026 AVR GlobeNewswire
Jun-08
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance AVR GlobeNewswire
May-13
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors AVR GlobeNewswire
May-12
Anteris Announces Results for the First Quarter of 2026 AVR GlobeNewswire
May-05
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial AVR GlobeNewswire
Apr-28
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial AVR GlobeNewswire
Feb-26
Anteris Reports 2025 Financial Results and Provides Corporate Update AVR GlobeNewswire
Feb-23
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays AVR +8.45% GlobeNewswire
Jan-22
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises AVR +8.42% GlobeNewswire
Jan-22
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock AVR +8.42% GlobeNewswire
Jan-20
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering AVR +5.39% GlobeNewswire
Jan-20
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic AVR +12.52% AVR +5.39% GlobeNewswire
Nov-17
Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves AVR GlobeNewswire
Nov-12
Anteris Announces Results for the Third Quarter of 2025 AVR GlobeNewswire
Nov-03
FDA Approves Anteris's DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Oct-28
Anteris DurAVR THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year AVR -7.84% AVR -8.71% GlobeNewswire
Oct-27
Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Oct-27
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR THV to be Presented at TCT 2025 AVR GlobeNewswire
Oct-15
Anteris Receives First European Regulatory Clearance to Commence DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Sep-19
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders AVR GlobeNewswire
Sep-11
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders AVR GlobeNewswire
Sep-04
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders AVR GlobeNewswire
Aug-11
Anteris Announces Results for the Second Quarter of 2025 AVR AVR +6.00% GlobeNewswire
Jun-09
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors AVR GlobeNewswire
May-13
Anteris Announces Results for the First Quarter of 2025 AVR AVR -9.89% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)